

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68		(11) International Publication Number: WO 00/15834
A2		(43) International Publication Date: 23 March 2000 (23.03.00)
<p>(21) International Application Number: PCT/CA99/00852</p> <p>(22) International Filing Date: 15 September 1999 (15.09.99)</p> <p>(30) Priority Data: 60/100,311 15 September 1998 (15.09.98) US</p> <p>(71) Applicant (for all designated States except US): SIGNALGENE INC. [CA/CA]; 8475 Christophe Colomb Avenue, Montreal, Quebec H2M 2N9 (CA).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): ROUSSEAU, François [CA/CA]; 2540 Lalonde, Sainte-Foy, Quebec G1W 1M7 (CA).</p> <p>(74) Agents: DUBUC, Jean, H. et al.; Goudreau Gage Dubuc & Martineau Walker, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
(54) Title: MARKER AT THE ANDROGEN RECEPTOR GENE FOR DETERMINING BREAST CANCER SUSCEPTIBILITY		
(57) Abstract		

The present invention relates to a method of determining an individual's predisposition to breast cancer, development of breast cancer, protection against breast cancer and/or responsiveness to therapy for breast cancer. The method comprises the step of determining the androgen receptor genotype at the CAG repeat locus of an individual, or at a locus in linkage disequilibrium with the CAG repeat locus, thereby determining an individual's predisposition to breast cancer, development of breast cancer, protection against breast cancer and/or responsiveness to therapy for breast cancer.